ClinicalTrials.gg
CompletedNCT01910311Updated Jun 6, 2017Results posted

A Study of Baricitinib and Rifampicin in Healthy Participants

A Phase 1 interventional study of Baricitinib and Rifampicin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purposes of this study are to look at what effect multiple doses of rifampicin have on a single dose of baricitinib and to look at the safety and tolerability of these drugs. Side effects will be documented. The study will last approximately 31 days from the first dose to the end of the study.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females
  • Male participants: Agree to use 2 reliable methods of with female partners of during the study and for at least 3 months following the last dose of study drug
  • Female participants: Women not of childbearing potential due to surgical sterilization (at least 3 months after surgical hysterectomy, bilateral oophorectomy with or without hysterectomy, or bilateral tubal occlusion/ligation) confirmed by medical history, or menopause. Menopausal women are women with spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (for example, oral contraceptives, hormones, gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators, or chemotherapy). Menopausal status should be confirmed by a follicle-stimulating hormone (FSH) level greater than 40 international units per liter (IU/L) at screening [unless the participant is taking hormone replacement therapy (HRT)]
  • Have a body weight of ≥60 kilograms (kg) at the time of screening
  • Have clinical laboratory test results within normal reference range
  • Have normal renal function
  • Have normal blood pressure and pulse rate (supine position)
  • Have venous access sufficient to allow for blood sampling

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, have completed, or discontinued within the last 90 days from a clinical trial involving a study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have previously completed or withdrawn from this study or any other study investigating baricitinib, and have previously received the study drug
  • Have known allergies to baricitinib, rifampicin, related compounds, or any components of the baricitinib or rifampicin formulations, or history of significant atopy
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
  • Have an average weekly alcohol intake that exceeds 28 units per week (males) and 21 units per week (females), or are unwilling to stop alcohol consumption 48 hours prior to the first dose and until completion of the safety follow-up assessment [Day 18 ± 1; 1 unit = 12 ounces (oz) or 360 milliliters (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits]
  • Have a history of, in the opinion of the investigator, excessive methylxanthine use within previous 6 months, such as greater than (>)6 cups of coffee (or equivalent) per day
  • Currently smoke more than 10 cigarettes per day or are unable to abide by Clinical Research Unit (CRU) restrictions
  • Are unwilling to refrain from using soft contact lenses from the start of the second treatment period until after the final follow-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Baricitinib

    Single oral dose of 10 milligrams (mg) baricitinib on Day 1.

    Drug: Baricitinib

  • Experimental
    Baricitinib + Rifampicin

    Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.

    Drug: Baricitinib · Drug: Rifampicin

Interventions

06

What researchers measure

Primary outcomes

  1. PK: Maximum Concentration (Cmax) of Baricitinib

    Time frame: Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

  2. PK: Area Under the Concentration Versus Time Curve From 0 to Infinity [AUC(0-∞)] of Baricitinib

    Time frame: Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

  3. PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib

    Time frame: Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

07

Results

Posted Apr 21, 2017

Participant flow

Period 1 (Days 1-2)
Participant flow — Period 1 (Days 1-2)
MilestoneBaricitinib Then Baricitinib and Rifampicin
Started18
Received baricitinib18
Completed18
Not completed0
Period 2 (Days 3-32)
Participant flow — Period 2 (Days 3-32)
MilestoneBaricitinib Then Baricitinib and Rifampicin
Started18
Received baricitinib18
Received at least 1 dose of rifampicin18
Completed18
Not completed0

Outcome measures

PrimaryPK: Maximum Concentration (Cmax) of Baricitinib
Time frame:
Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Baricitinib
nanograms per milliliter (ng/mL)BaricitinibBaricitinib and Rifampicin
PK: Maximum Concentration (Cmax) of Baricitinib96.1 ± 22101 ± 28
PrimaryPK: Area Under the Concentration Versus Time Curve From 0 to Infinity [AUC(0-∞)] of Baricitinib
Time frame:
Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From 0 to Infinity [AUC(0-∞)] of Baricitinib
nanograms*hour/milliliter (ng*h/mL)BaricitinibBaricitinib and Rifampicin
PK: Area Under the Concentration Versus Time Curve From 0 to Infinity [AUC(0-∞)] of Baricitinib634 ± 19416 ± 20
PrimaryPK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
Time frame:
Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose
Reported as:
Median · hours (h)
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
hours (h)BaricitinibBaricitinib and Rifampicin
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib1.00 (0.50 to 2.00)1.00 (0.50 to 1.00)

Adverse events

Collected over Baseline through study completion (up to Day 32). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib—0/18 (0%)3/18 (16.7%)
Rifampicin—0/18 (0%)3/18 (16.7%)
Baricitinib and Rifampicin—0/18 (0%)5/18 (27.8%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventBaricitinibRifampicinBaricitinib and Rifampicin
NauseaGastrointestinal disorders1/180/182/18
NasopharyngitisInfections and infestations1/180/182/18
Abdominal pain upperGastrointestinal disorders0/180/181/18
FlatulenceGastrointestinal disorders0/180/181/18
Gingival bleedingGastrointestinal disorders0/181/180/18
VomitingGastrointestinal disorders0/180/181/18
Chest discomfortGeneral disorders1/180/180/18
FatigueGeneral disorders0/181/180/18
ThirstGeneral disorders0/181/180/18
ArthralgiaMusculoskeletal and connective tissue disorders0/181/180/18

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Baricitinib Then Baricitinib and Rifampicin
Mean40.9 ± 15.4
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib Then Baricitinib and Rifampicin
Female3
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib Then Baricitinib and Rifampicin
Hispanic or Latino0
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib Then Baricitinib and Rifampicin
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White16
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Baricitinib Then Baricitinib and Rifampicin
United Kingdom18
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2013
First posted
Jul 29, 2013
Start
Aug 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Apr 21, 2017
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01910311
Responsible party
Sponsor
First posted
Jul 29, 2013
Start date
Aug 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Apr 21, 2017
Last update
Jun 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion